Shanghai ZhenGe Biotech, a Shanghai, China-based company focused on providing a macromolecular biological drug CDMO service, raised USD100M in Series C funding. The round was led by Goldman Sachs Asset Management and Sofina with participation from Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital. The company, which has raised a total of US$225m to date, intends to use the funds to expand its Good Manufacturing Practice (“GMP”) manufacturing capacity to better meet demand from domestic and international clients. Led by Mr. Jianxin Chen, Chairman and CEO, Shanghai ZhenGe Biotech provides Contract Development and...